Capital Advisors Inc. OK Acquires 16,242 Shares of Medtronic plc (NYSE:MDT)

Capital Advisors Inc. OK boosted its stake in shares of Medtronic plc (NYSE:MDT - Free Report) by 5.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 332,273 shares of the medical technology company's stock after purchasing an additional 16,242 shares during the quarter. Capital Advisors Inc. OK's holdings in Medtronic were worth $26,542,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of MDT. Signet Investment Advisory Group Inc. raised its position in shares of Medtronic by 2.8% during the fourth quarter. Signet Investment Advisory Group Inc. now owns 21,977 shares of the medical technology company's stock valued at $1,756,000 after buying an additional 600 shares during the last quarter. Leavell Investment Management Inc. increased its stake in Medtronic by 4.4% during the fourth quarter. Leavell Investment Management Inc. now owns 5,331 shares of the medical technology company's stock valued at $430,000 after acquiring an additional 226 shares during the period. Portfolio Design Labs LLC raised its holdings in Medtronic by 67.4% in the 4th quarter. Portfolio Design Labs LLC now owns 4,422 shares of the medical technology company's stock valued at $353,000 after acquiring an additional 1,781 shares in the last quarter. Sovran Advisors LLC bought a new stake in shares of Medtronic in the 4th quarter worth approximately $415,000. Finally, Strengthening Families & Communities LLC lifted its position in shares of Medtronic by 8.6% in the 4th quarter. Strengthening Families & Communities LLC now owns 23,118 shares of the medical technology company's stock worth $1,847,000 after acquiring an additional 1,833 shares during the period. 82.06% of the stock is owned by institutional investors.

Medtronic Price Performance

Shares of MDT traded up $0.15 on Wednesday, hitting $91.35. The company's stock had a trading volume of 7,053,193 shares, compared to its average volume of 7,167,588. The company has a market capitalization of $117.14 billion, a PE ratio of 27.94, a PEG ratio of 2.57 and a beta of 0.84. Medtronic plc has a fifty-two week low of $75.96 and a fifty-two week high of $93.08. The company has a 50 day moving average price of $85.04 and a 200 day moving average price of $86.65. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.84 and a quick ratio of 1.39.

Medtronic (NYSE:MDT - Get Free Report) last posted its quarterly earnings data on Tuesday, November 19th. The medical technology company reported $1.26 EPS for the quarter, topping analysts' consensus estimates of $1.25 by $0.01. Medtronic had a return on equity of 13.79% and a net margin of 13.00%. The company had revenue of $8.40 billion for the quarter, compared to analyst estimates of $8.27 billion. During the same quarter in the previous year, the firm earned $1.25 earnings per share. The business's revenue was up 5.2% on a year-over-year basis. On average, research analysts anticipate that Medtronic plc will post 5.45 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 10th. Shareholders of record on Friday, December 27th were issued a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a yield of 3.07%. The ex-dividend date of this dividend was Friday, December 27th. Medtronic's dividend payout ratio is currently 85.63%.

Insider Buying and Selling at Medtronic

In other Medtronic news, EVP Brett A. Wall sold 12,437 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $90.00, for a total value of $1,119,330.00. Following the transaction, the executive vice president now directly owns 40,979 shares in the company, valued at approximately $3,688,110. This trade represents a 23.28 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.20% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Robert W. Baird cut their target price on Medtronic from $96.00 to $93.00 and set a "neutral" rating for the company in a research note on Wednesday, November 20th. Wells Fargo & Company lowered their price target on shares of Medtronic from $106.00 to $98.00 and set an "overweight" rating on the stock in a report on Wednesday, November 20th. Sanford C. Bernstein raised their price objective on shares of Medtronic from $96.00 to $97.00 and gave the stock an "outperform" rating in a report on Wednesday, November 20th. Barclays lifted their target price on shares of Medtronic from $105.00 to $109.00 and gave the company an "overweight" rating in a research report on Tuesday, November 26th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Medtronic in a research report on Wednesday. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $95.00.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.